Actelion Setback Ahead Of J&J Deal Closure
A setback for Actelion – and Johnson & Johnson – as it reports mixed Phase III data for the Clostridium difficile treatment candidate cadazolid.
A setback for Actelion – and Johnson & Johnson – as it reports mixed Phase III data for the Clostridium difficile treatment candidate cadazolid.